# Insulin Signaling in Skeletal Muscle

> **NCT03452267** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Wayne State University**

## Conditions studied

- Insulin Sensitivity

## Interventions

- **DRUG:** Metformin
- **DRUG:** Pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03452267
- **Lead sponsor:** Wayne State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452267, "Insulin Signaling in Skeletal Muscle". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03452267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*